Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Disease and Therapy Review: Non-Small Cell Lung Cancer' returned 38 results - Page 1 of 2  FEATURED RESULTS Cancer Diagnostic Testing World Markets Drug Delivery in Cancer - Technologies, Markets and Companies Antibody Drug Target Atlas in Oncology Cancer Vaccines and Tumor Immunity Anticancer Therapeutics   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Salient Review Non-Small Cell Lung Cancer: Advances in Blood Biomarkers, 2011   BioPharm Reports (VennBio Ltd.), Oct 2011, Pages: 60 This Salient Review presents the findings of more than 150 clinical studies or commercial disclosures relating to non-small cell lung cancer biomarkers, in the blood. These findings, which were Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2012   GlobalData, Jan 2012, Pages: 167 Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2011" provides data Disease and Therapy Review: Lung Cancer   Timely Data Resources, Inc., Dec 2011, Pages: 15 websites.  Sources and references are provided.   The Lung Cancer Disease and Therapy Review provides an overview of small cell and non-small cell lung cancer, with incidence, prevalence, and mortality Individualizing and Monitoring Cancer Therapy   Future Medicine Ltd, Aug 2010, Pages: 92 in head and neck cancer, gene mutation in colorectal and non-small cell lung cancer, and epigenetic aberrations. EDITORIAL: - Today’s discoveries to tomorrow’s care: cancer biomarkers revisited CJ Rosser Vaccines in Clinical trials: Cancer   Expert Reviews Ltd, June 2011, Pages: 210 Wheeler, Keith L Black - Non-small-cell lung carcinoma vaccines in clinical trials Antonio Rossi, et al - Colorectal cancer vaccines in clinical trials Frank M Speetjens, et al Vaccines in Clinical Cancer Therapies - Global Strategic Business Report   Global Industry Analysts, Inc., Oct 2011, Pages: 897 to drive cancer therapy market in the future. Currently approved combination therapies include paclitaxel, and carboplatin together with Avastin indicated for the treatment of non-small cell lung cancer Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker   Espicom Business Intelligence Ltd, Sep 2007 development. These products look set to target some of the "big" cancers, with launches for vaccines against renal cell carcinoma, melanoma, prostate, non-small cell lung and colorectal cancer Cancer Vaccine Developments to 2013   Espicom Business Intelligence Ltd, Sep 2007, Pages: 184 renal cell carcinoma, melanoma, prostate, non-small cell lung and colorectal cancer. But there are many challenges ahead It is still not clear how best to use cancer vaccines with respect to disease Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development   GBI Research, Dec 2011, Pages: 215 indications, which includes breast cancer, colorectal cancer, Non-Hodgkin’s lymphoma (NHL), Non-Small Cell Lung Cancer (NSCLC), prostate cancer, ovarian cancer, cervical cancer and head and neck cancer Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter   Espicom Business Intelligence Ltd, March 2009, Pages: 206 of non-small cell lung cancer (NSCLC), the market is currently driven by chemotherapeutic agents such as the taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer Non-Small Cell Lung Cancer - Pipeline Review, H2 2011   Global Markets Direct, Sep 2011, Pages: 605 disease. Scope - A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer. - A review of the Non-Small Cell Lung Cancer products under development by companies and universities Lung Cancer Drug Pipeline Update 2011   Bioseeker, Feb 2011 Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R Non-Small Cell Lung Cancer - Pipeline Review, Q1 2011   Global Markets Direct, Feb 2011, Pages: 538 disease. Scope - A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer. - A review of the Non-Small Cell Lung Cancer products under development by companies and universities Hematology and Medical Oncology Best Practices   CME Group, Dec 2009 , Cleveland Clinic Taussig Cancer Center, Cleveland, OH - Non-Small Cell Lung Cancer - Small Cell Lung Cancer Bruce E. Johnson, MD Program Director, Lowe Center for Thoracic Oncology, Lowe Center for Thoracic Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018   GlobalData, Jan 2012, Pages: 147 and the US, Oncovex for melanoma Stimuvax (BLP25 liposome vaccine) for unresectable stage III NSCLC (non-small cell lung cancer). Due to the launch of first-in-class vaccines during the forecast Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report   Global Industry Analysts, Inc., Feb 2011, Pages: 682 Cancer Treatment 68 Genentech Receives FDA Approval for Bevacizumab in Non-Small Cell Lung Cancer 68 Amgen Obtains FDA Approval for Vectibix Treating mCRC 69 FDA Grants Marketing Approval for Lucentis The 2011 ASCO (American Society of Clinical Oncology) Annual Meeting - Post Conference Review and Analysis   GlobalData, June 2011, Pages: 82 trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy Oxford Gene Technology - Product Pipeline Analysis   GlobalData, Nov 2011, Pages: 17 Cancer Product Status Product Description Genomic Biomarker Assay – Prostate Cancer Product Status Product Description Non-Small Cell Lung Cancer Diagnostic Assay Product Status Product Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017   GlobalData, May 2011, Pages: 135 incidence will compound the growing demand for malignancy assays. This has led to a rise in the number of new tumor markers tests for cancers such as cervical cancer, NSCLC (non-small cell lung cancer Talactoferrin Alfa (NSCLC) - Analysis and Forecasts to 2020   GlobalData, Oct 2011, Pages: 35 , Non Small Cell Lung Cancer, NSCLC, Pipeline, Agennix AG, Oral Biologic Therapy, Avastin, Alimta, Erbitux, First Line Therapy of Locally Advanced NSCLC and Metastatic NSCLC, Alimta, Second Line Therapy Results:  First -   Prev -   1 -   2 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network